Press Releases Theranexus

Equities

ALTHX

FR0013286259

Real-time Euronext Paris Other stock markets 15:23:23 13/05/2024 BST			5-day change	1st Jan Change
1.06 ^EUR	-5.36%		-3.64%	-5.36%

04-29	Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-19	Theranexus: share price rises following promising trial results	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theranexus : THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT	04-29	AT
Theranexus : Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide	04-23	AT
Theranexus : Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1	04-18	AT
Theranexus : THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN	03-11	AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS	02-14	AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023	17/10/23	AT
Theranexus : Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1	29/09/23	AT
Theranexus : THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS	28/09/23	AT
Theranexus : Theranexus raises around 3.1 million euros in fundraising	12/07/23	AT
Theranexus : Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)	14/06/23	AT
Theranexus : Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to evaluate Batten-1 in CLN3 Batten disease	09/05/23	AT
Theranexus : THERANEXUS PUBLISHES ITS 2022 FULL-YEAR RESULTS AND PRESENTS AN UPDATE ON ITS PROGRAMS	12/04/23	AT
Theranexus : THERANEXUS, BBDF AND CARDIFF UNIVERSITY PRESENT THEIR NOVEL RESEARCH ON BATTEN-1 AND BATTEN DISEASE AT WORLDSYMPOSIUM 2023	20/02/23	AT
Theranexus : AISTROSIGHT: NEW JOINT PROJECT TEAM BETWEEN THERANEXUS, INRIA, CLAUDE BERNARD UNIVERSITY LYON 1 AND HOSPICES CIVILS DE LYON TARGETING RARE NEUROLOGICAL DISEASES	10/02/23	AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2022 AND ANNOUNCES ORGANIZATIONAL CHANGES	18/01/23	AT
Theranexus : Présentation JPM / Biotech showcase / Sachs Forum	05/01/23	PU
Theranexus : New advance to the Theranexus and BBDF Batten-1 program for juvenile Batten disease (CLN3)	05/01/23	AT
Theranexus : THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2023	21/12/22	AT
Theranexus : THERANEXUS ANNOUNCES PARTICIPATION IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 9-12, 2023 IN SAN FRANCISCO	20/12/22	AT
Theranexus : THERANEXUS AND BBDF PRESENT PROGRESS ON THE BATTEN-1 PROGRAM AT THE TRANSLATIONAL RESEARCH CONFERENCE FOR THE MANAGEMENT OF NCLS ON 3 AND 4 NOVEMBER, 2022 IN CHICAGO	02/11/22	AT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Theranexus

Equities

ALTHX

FR0013286259

Press Releases

Filters